A University of Colorado professor won the 2024 Alton Ochsner Award for his work on disease risk factors for idiopathic ...

The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...

Findings of a systematic review highlight the need for standardized assessment tools and targeted treatments for chronic ...

In addition to pulmonary fibrosis, columnist Ann Reynoso is now also dealing with sleep apnea — both of which affect her ...

Ioannis Sapountzis, head of global therapeutic areas at Boehringer, said that FIBRONEER-IPF is the largest trial in IPF ...

The Hong Kong headquartered company says its idiopathic pulmonary fibrosis drug performed well in a phase 2a trial and met ...

IPF is a rare progressive fibrosing interstitial lung disease with symptoms that include breathing difficulty, dry and persistent cough, chest discomfort and fatigue. The randomized, double-blind, ...

Boehringer Ingelheim announced today that the FIBRONEERTM-IPF trial met its primary endpoint, which was the absolute change ...

The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.

Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, announced positive preliminary results ...

Albert Agro, PhD, CMO of GRI Bio recently participated in a Virtual Investor KOL Connect segment with prominent key opinion ...

Insilico Medicine has announced positive preliminary results from its Phase IIa clinical trial of ISM001-055, a small ...